Evidence supporting the use of: Cannabinoids
For the health condition: Crohn's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabinoids, including compounds such as THC and CBD found in cannabis, have been explored for their potential therapeutic effects in Crohn's Disease, an inflammatory bowel disease (IBD). The interest is based on the discovery that the endocannabinoid system plays a role in regulating gastrointestinal motility, inflammation, and immune responses. Some small clinical studies and patient surveys have shown symptomatic improvement in Crohn’s Disease patients using cannabinoids, particularly in pain relief, appetite stimulation, and overall well-being. For example, a small randomized controlled trial published in Clinical Gastroenterology and Hepatology (Naftali et al., 2013) found that inhaled cannabis induced clinical remission in a subset of Crohn's Disease patients who were refractory to standard therapy. However, this and other studies have been limited by small sample sizes, short durations, and lack of robust placebo controls.

Systematic reviews and meta-analyses generally conclude that while cannabinoids may improve symptoms, there is insufficient evidence to support their use for reducing intestinal inflammation or achieving long-term remission. Major gastroenterology organizations do not currently recommend cannabinoids as a primary treatment for Crohn’s Disease, citing the need for larger, high-quality trials. In summary, while there is some scientific investigation and anecdotal support, the current clinical evidence for cannabinoids in Crohn's Disease is low to moderate, justifying a rating of 2 out of 5.

More about Cannabinoids
More about Crohn's Disease

Products containing Cannabinoids

We currently have no products on Vitabase that contain this ingredient.